Where a clinical investigation is to be conducted to further assess, within the scope of its intended purpose, a device which already bears the CE marking in accordance with Article 20(1), (‘PMCF investigation’), and where the investigation would involve submitting subjects to procedures additional to those performed under the normal conditions of use of the device and those additional procedures are invasive or burdensome, the sponsor shall notify the Member States concerned at least 30 days prior to its commencement by means of the electronic system referred to in Article 73.
I gcás ina bhfuil imscrúdú cliniciúil le déanamh chun measúnú breise a dhéanamh, laistigh de raon feidhme na críche a beartaíodh di, ar fheiste a bhfuil an mharcáil CE uirthi cheana féin i gcomhréir le hAirteagal 20(1), (“imscrúdú MLCI”), agus i gcás ina mbeadh i gceist leis an imscrúdú ábhair a chur faoi réir gnáthaimh de bhreis orthu siúd a dhéantar faoi ghnáthdhálaí úsáide na feiste agus gur gnáthaimh ionracha nó gnáthaimh a mbeadh ualach breise i gceist leo iad, tabharfaidh an t-urraitheoir fógra do na Ballstáit lena mbaineann 30 lá ar a laghad sula dtosóidh sé, trí bhíthin an chórais leictreonaigh dá dtagraítear in Airteagal 73.